June 30th, 2021 | 12:07 CEST
SAP, Barsele Minerals, BioNTech - Shares have no alternative
Table of contents:
SAP - Quarterly figures will set the tone
As experience shows, SAP is one of the first to present its quarterly figures, and it promises to be exciting. CFO Mucic recently warned about the exchange rates, which have deteriorated even further since the announcement of the first quarter. The euro's strength is weighing on the Group's results, as a large part of its sales are generated abroad. The other exciting question is whether SAP has managed to maintain the growth in its cloud business from the first quarter.
There is hope that the digitization wave unleashed by Corona will ensure full order books. The cloud strategy will also positively impact the medium term, as the Company can offer solutions for all business areas. The advantage of this is that the issue of cybersecurity, which is increasingly coming into focus, only has to be considered in one place, in the cloud structure. On the one hand, this reduces costs for the Group's customers, and on the other, it also leads to better customer loyalty.
SAP still earns most of its money from the license business, but cloud services are expected to catch up soon and become a profit driver. The CFO hopes for double-digit growth in earnings from 2023. The share is still in an intact upward trend and is attempting to break through the resistance at EUR 121 for the third time. If it succeeds, the next level is at EUR 135.
Barsele Minerals - A gold treasure
Barsele Minerals was an investment company until a few weeks ago. That changed on May 12 with a letter of intent to purchase Agnico Eagle's 55% stake in the Barsele project. The purchase price is USD 45 million, plus 14.9% of Barsele Minerals shares, 6 million warrants and 2% royalty. As a result, Barsele Minerals would be the sole owner of the proven gold deposit of 2.5 million ounces. The property is located in northern Sweden, covers 33,500 hectares, and has a long mining history. There are also active mines in the area.
The former partner has drilled over 400 drill holes totaling approximately 156,000 meters of drilling in recent years. From this, the resource estimate of 2.5 million ounces was produced. Barsele Minerals plans to drill another 30,000m in the main deposit area to prove even more gold over the next 18 months. A target of 3.5 million ounces has been issued. If successful, the site would be of interest to any gold producer globally, and the Company would be a potential takeover candidate. The transaction should be completed by the end of July, but this can be postponed by a month under certain conditions.
In addition to the main gold deposit, there is another area called the Norra Zone, which has massive volcanic sulfide and where Agnico has already shown promising samples. Management has a 25% stake in the Company and is vested in making this project fly. After the spike to CAD 0.82, the stock fell to around CAD 0.70 due to the announcement. Establishing a first position here could be worthwhile. If the goals are achieved, doubling is easily possible.
BioNTech - New study carries risks
BioNTech is considered the most popular vaccine and is made in Germany. Shareholders have been able to enjoy constantly rising prices since the start of the stock market. Every setback was used to buy. This is also thanks to the good news. Because despite all mutations, including the delta variant, the vaccine should help, as stated by Company founder Sahin at the recent Annual General Meeting. The Company is constantly analyzing its effectiveness against new mutations.
In addition, the failure of competitor CureVac means one less competitor on the market for now. Since the middle of last week, the upward trend has stopped, which is due to media reports assuming that the vaccine will be effective for a long time. The status so far was that one would probably need a booster every 6 months. A study published in Nature magazine assumes much longer protection, which would mean fewer vaccine sales.
Separate from this, one must consider the wide range of other drugs in development. Twenty-two are currently in the pipeline. The vaccine has paved the way for breakthroughs in a wide range of diseases. Against this backdrop, the stock is a value with a lot of imagination. Nevertheless, one must expect setbacks, as in the discussion about the cancellation of the patents. Currently, one should look at the further course, as the study could cause uncertainty.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.
Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.